Opinion|Videos|March 31, 2026
Approaching Frontline Therapy in HER2-Mutant NSCLC
Author(s)Martin Dietrich, MD, PhD, Ticiana A. Leal, MD
Martin F. Dietrich, MD, PhD, and Ticiana Leal, MD, discuss frontline therapy approaches in HER2-mutant non–small cell lung cancer and the evolving role of chemoimmunotherapy.
Advertisement
Episodes in this series
Martin F. Dietrich, MD, PhD, and Ticiana Leal, MD, discuss current approaches to frontline therapy in HER2-mutant non–small cell lung cancer. Dietrich reviews the ongoing role of chemotherapy with or without immunotherapy, particularly in the absence of upfront targeted options. Leal highlights considerations for deferring HER2-directed therapies to later lines and how these decisions are framed in clinical discussions with patients.
Advertisement
Related to this article
Researchers at Wake Forest University School of Medicine identified a protein that may help breast cancer spread to the brain and evade immune defenses.
Benjamin Weinberg, MD, discusses the FDA approval of daraxonrasib, RASolute 302 survival data, safety considerations, and future RAS-targeted therapies in pancreatic cancer.
Half of lenalidomide-refractory patients with 1 to 3 prior lines remained alive and progression free at least 5 years after a single cilta-cel infusion.
Andrew Kuykendall, MD, discusses the FDA approval of rusfertide and how to apply it in clinical practice for polycythemia vera management.
An NDA seeks FDA approval of savolitinib plus osimertinib for EGFR-mutated NSCLC with MET overexpression or amplification after EGFR TKI therapy.
Jason Hafron, MD, discusses the emotional, clinical, and financial burden of false positive cancer screening results and improved risk stratification.
Raajit K. Rampal, MD, PhD, discusses JAK inhibitor choice in cytopenic myelofibrosis, emerging combinations, and anemia-directed agents.
The sNDA for elinzanetant seeks FDA approval for moderate-to-severe vasomotor symptoms in women receiving endocrine therapy for HR-positive breast cancer.
Advertisement
Advertisement
Trending on OncLive
1
China's NMPA Approves Pirtobrutinib Across CLL
2
FDA Grants Priority Review to Elinzanetant for Endocrine Therapy–Associated Vasomotor Symptoms in HR+ Breast Cancer
3
Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma
4
Calculating the Real Cost of False Positive Findings in Cancer Screening
5